NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...
26 May 2015 - 9:30PM
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a
biopharmaceutical company developing novel, cell-based
individualized medicine therapies, today announced the appointment
of Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma
Section, Department of Surgical Oncology, The University of Texas
MD Anderson Cancer Center (MD Anderson), as the lead principal
investigator for NeoStem's Intus study. The Intus study is a Phase
3 clinical trial investigating the efficacy of the Company's
patient-specific targeted cancer immunotherapy candidate NBS20
(USAN = eltrapuldencel-T) in patients with stage III recurrent or
stage IV metastatic melanoma. "I have dedicated my career to
helping patients with cancer to live the longest, highest-quality
lives they can in each individual case," said Dr. Ross. "I have
seen melanoma treatments evolve over the past 30 years and am
looking forward to serving as study chairman for this pivotal Phase
3 trial." Dr. Ross is a surgical oncologist with specific expertise
in melanoma who has worked and taught at MD Anderson since 1989.
Dr. Ross has published extensively in medical literature,
frequently lectures both domestically and abroad and has been in
leadership roles for several completed melanoma clinical trials at
the institutional, national, and international level. He has also
been the recipient of various honors, including the Charles M.
McBride Distinguished Professorship in Surgical Oncology. Dr. Ross
received his medical degree from the University of Illinois School
of Medicine in Chicago, completed a residency in General Surgery at
the University of Illinois Affiliated Hospitals in Chicago, and was
Chief Resident at the University of Illinois Department of Surgery.
Additionally, Dr. Ross completed a research fellowship at Scripps
Clinic and Research Institute in La Jolla, California, and a
surgical oncology fellowship at The University of Texas MD Anderson
Cancer Center. "We are very fortunate to have Dr. Ross serve as the
lead principal investigator for the Intus study," said Dr. Douglas
Losordo, Chief Medical Officer of NeoStem. "His expertise as a
surgical oncologist and experience in melanoma particularly make
him an invaluable resource to the trial as we work to advance
NBS20. We are delighted to welcome the leadership of this esteemed
physician-scientist."
For more information on the Intus Study please visit
www.theintusstudy.com or
www.clinicaltrials.gov/ct2/show/NCT01875653.
About NeoStem NeoStem, Inc. is among the first
of a new breed of immunotherapy companies with proven
expertise and unique experience in cell process optimization,
development, and manufacturing. NeoStem is a cell therapy leader
with late-stage clinical programs based on a proprietary platform
technology for immuno-oncology, as well as additional platform
technologies for ischemic repair and immunomodulation, and
capabilities that support other cell therapy developers. This
integrated approach supports the industry in bringing significant
life-improving medical treatments to market. www.neostem.com.
Forward-looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the
date of this press release, and involve certain risks and
uncertainties. Forward-looking statements include statements herein
with respect to the successful execution of the Company's business
strategy, the Company's ability to develop and grow its business,
the successful development of cellular therapies with respect to
the Company's research and development and clinical evaluation
efforts in connection with the Company's Immuno-Oncology Program,
Ischemic Repair Program, Immune Modulation Program and other cell
therapies, the future of the regenerative medicine industry and the
role of stem cells and cellular therapy in that industry, and the
performance and planned expansion of the Company's wholly-owned
subsidiary and its center of excellence for cell therapy process
development, engineering and manufacturing, PCT. The Company's
further development is highly dependent on future medical and
research developments and market acceptance, which is outside of
its control. The Company's actual results could differ materially
from those anticipated in these forward-looking statements as a
result of various factors. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see the
factors described under the heading, "Item 1A. Risk Factors"
in the Company's Annual Report on Form 10-K filed with the SEC on
March 2, 2015 and those described in the Company's other periodic
filings with the SEC. The Company undertakes no obligation to
update or revise any forward-looking statements.
CONTACT: NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024